Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Other Non-Current Liabilities: 2024-2025

Historic Other Non-Current Liabilities for Kura Oncology (KURA) over the last 2 years, with Sep 2025 value amounting to $3.0 million.

  • Kura Oncology's Other Non-Current Liabilities rose 102.65% to $3.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.0 million, marking a year-over-year increase of 102.65%. This contributed to the annual value of $1.8 million for FY2024, which is N/A change from last year.
  • Per Kura Oncology's latest filing, its Other Non-Current Liabilities stood at $3.0 million for Q3 2025, which was up 14.87% from $2.6 million recorded in Q2 2025.
  • In the past 5 years, Kura Oncology's Other Non-Current Liabilities ranged from a high of $3.0 million in Q3 2025 and a low of $951,000 during Q1 2024.
  • Its 2-year average for Other Non-Current Liabilities is $1.9 million, with a median of $1.8 million in 2024.
  • Data for Kura Oncology's Other Non-Current Liabilities shows a peak YoY spiked of 124.92% (in 2025) over the last 5 years.
  • Quarterly analysis of 2 years shows Kura Oncology's Other Non-Current Liabilities stood at $1.8 million in 2024, then skyrocketed by 102.65% to $3.0 million in 2025.
  • Its Other Non-Current Liabilities was $3.0 million in Q3 2025, compared to $2.6 million in Q2 2025 and $2.1 million in Q1 2025.